BSE filing, NSE: GODAVARI. Summary written from the filing by ALFA Finder's alert engine.
Godavari Drugs Ltd: key numbers
- Share price
- ₹119.35
- Market cap
- ₹120.9 Cr
- Revenue (annual)
- ₹105.8 Cr
- Net profit (annual)
- ₹4.09 Cr
- P/E (TTM)
- 29.1×Sector 37.9×
- Promoter holding
- 40.23%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Godavari Drugs Ltd
All →Godavari Drugs Other Announcement
Godavari Drugs Limited changed its Corporate Identification Number (CIN) following an alteration to its Memorandum of Association's Object Clause. The Ministry of Corporate Affairs registered the change on October 16, 2026.
Godavari Drugs Debt & Borrowing: ₹34 Cr
Godavari Drugs Limited's board approved availing working capital limits of Rs. 34 Crore from ICICI Bank. The facility is within existing shareholder-approved borrowing limits.
- Value
- ₹34.00 Cr
Godavari Drugs Annual General Meeting
Godavari Drugs held its 38th Annual General Meeting on September 25, 2026, via video conferencing. Shareholders approved financial statements, director re-appointment, and object clause alteration.
Godavari Drugs Annual General Meeting
Godavari Drugs Limited will close its register of members and share transfer books from September 19 to September 25, 2026, for its 38th Annual General Meeting.
Godavari Drugs Board Meeting Outcome
Godavari Drugs approved altering its Memorandum of Association to add a nutraceuticals business object. A revised notice for the 38th AGM was also approved.
Godavari Drugs Capital Structure Change
Godavari Drugs Limited allotted 7,86,690 equity shares to the promoter category following warrant conversion. The company received Rs. 5.25 Crore, representing the final 75% payment.
- Value
- ₹5.25 Cr
Other other announcement announcements
All →Keerthi Industries Other Announcement
Keerthi Industries reported nil requests for the re-lodgement of physical share transfers for October 2026. The report follows SEBI guidelines regarding a special window for dematerialisation.
Kesar India Other Announcement
Kesar India reported no deviation or variation in the use of its preferential issue proceeds for the quarter and half year ended 30 September 2026. The statement was reviewed by the Audit Committee and taken on record by the Board.
Filtron Engineers Other Announcement
Filtron Engineers filed its Regulation 32 statement of deviations or variations for funds raised through a preferential issue for the quarter ended September 30, 2026. It reports no deviation, with Rs. 1,590 lakhs raised on 17/12/2025 and utilisation shown.
Bharti Hexacom Other Announcement
Bharti Hexacom informed the exchanges that its RTA, KFin Technologies, will move its corporate office effective December 1, 2026. The registered office of the RTA is unchanged.
Dr. Reddy's Laboratories Other Announcement
Dr Reddy's KMP Erez Israeli sold 460,276 ADRs to cover the exercise of 591,270 ADRs allotted under ESOP. The disposal is valued at about ₹61.76 Crore.
- Value
- ₹61.76 Cr
Addictive Learning Technology Other Announcement
Addictive Learning Technology filed its half-year IPO proceeds utilisation statement under Reg 32. Reallocations moved Rs.521.32 lakh to working capital, with Rs.200 lakh unused.